| Sebelius Defends Medicare Nominee Health secretary Kathleen Sebelius rejected criticism of the Obama administration's nominee to run Medicare and Medicaid, saying Republicans were being unfair to Donald Berwick and she was confident he would be confirmed. online.wsj.com |
MannKind's Large Put Spread optionMONSTER submits: By Chris McKhannThe implied volatility for MannKind (MNKD) is climbing off its 52-week low, and with that comes a big put spread today.Complete Story » seekingalpha.com |
Genzyme Shareholder Files Suit to Block Sanofi Deal: Biotech's Latest Mishaps The Burrill Report submits: A Genzyme (GENZ) shareholder has filed suit to prevent the company from entering into an acquisition agreement with Sanofi-Aventis (SNY), The Boston Globe reported. Sanofi reportedly offered $69 a share or $18.4 billion to buy the Cambridge, Massachusetts-based biotech, although neither company has publicly commented on any offer or ongoing negotiations. The suit, filed in Superior Court in Woburn, Massachusetts, charges that selling the company to Sanofi at the price being discussed would be a breach of the Genzyme’s board fiduciary responsibility because it would represent a discount to its true value. The suit seeks class-action status. Eli Lilly (LLY) said it will halt development of its experimental drug to treat Alzheimer’s semagacestat because preliminary results from two ongoing long-term phase 3 studies showed it failed to slow disease progression and was associated with worsening of cognition and the ability to perform activities of daily living. The company said its decision does not affect the ongoing clinical trials of solanezumab, Lilly's other compound in phase 3 trials as a potential Alzheimer's treatment. While both drugs focus on amyloid-beta proteins, which are believed to play a critical role in Alzheimer's disease, they have different mechanisms of action. Lilly also has two other compounds in earlier stages of clinical development; those studies are not affected by the announcement.Complete Story » seekingalpha.com |
ERT to Present at UBS Global Life Sciences Conference on September 20, 2010 [PR Newswire] - ERT , announced today that Dr. Michael J. McKelvey, the Company's President and CEO, and Keith Schneck, the Company's Executive Vice President and CFO, are scheduled to present at UBS Global Life Sciences Conference at 11:30 AM EDT on September 20, 2010 in New York City, New York. us.rd.yahoo.com |
Hollywood Stars Talk About Epilepsy - Video Hollywood Movie Premiere Highlights National Epilepsy Awareness Month feedproxy.google.com |